Rein Therapeutics RNTX 深 沪
已收盘 09-04 16:00:00 美东时间
0.8891
+0.046
+5.39%
华盛通- 最 高0.92
- 今 开0.92
- 成交量 98.60万股
- 最 低 0.85
- 昨 收 0.8436
- 总市值 7670.00万
- 52周最高 2.18
- 市盈率 静 --
- 换手率 1.14%
- 52周最低 0.694
- 委 比 35.81%
- 总股本 8626.70万
- 历史最高 309.60
- 量 比 2.23
- 振 幅 8.30%
- 历史最低 0.694
- 每 手 1
- 风险率 0.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rein Therapeutics Highlights LTI-03 Progress in IPF
Rein Therapeutics ( ($RNTX) ) has shared an update. On September 4, 2026, Rein ...
09-05 05:24
Rein Therapeutics To Present Data On Inhaled LTI-03 For Idiopathic Pulmonary Fibrosis At European Respiratory Society 2026 Congress
Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress taking place...
09-04 20:02
Rein Therapeutics to Present at Upcoming September Investor Conferences
Rein Therapeutics' CEO Brian Windsor will present at two September investor conferences: the 2026 Cantor Global Healthcare Conference on September 11, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, both in New York. Live webcasts and replays will be available on the company's website. Rein Therapeutics focuses on developing first-in-class therapies for orphan pulmonary and fibrosis indications, with ...
09-03 20:01
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:RNTX) with a Buy and maintains $8 price target.
08-18 19:36
Rein Therapeutics Q2 EPS $(0.10) Beats $(0.17) Estimate
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 64.29 percent increase over losses of $(0.28) per share from the same period last year.
08-14 18:47
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
Maxim Group Initiates Coverage On Rein Therapeutics with Buy Rating, Announces Price Target of $4
Maxim Group analyst Jason McCarthy initiates coverage on Rein Therapeutics (NASDAQ:RNTX) with a Buy rating and announces Price Target of $4.
07-21 02:13
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
HC Wainwright & Co. Maintains Buy on Rein Therapeutics, Lowers Price Target to $8
HC Wainwright & Co. analyst Brandon Folkes maintains Rein Therapeutics (NASDAQ:RNTX) with a Buy and lowers the price target from $10 to $8.
06-01 18:42
